Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 21INDUSTRY 7NIH 5NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Meningioma 2Brain Neoplasms 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 84Gemcitabine 74Carboplatin 67Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Hydroxyurea × Clear all
NCT06326190 2025-09-16

LUMEN-1

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Recruiting
136 enrolled
CNS

Meningioma

NCT00003590 2016-05-20

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

SWOG Cancer Research Network

Phase 2 Completed
29 enrolled 5 charts
CNS

Brain Neoplasms, Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡